Lower flood insurance premiums coming for James Island homeowners
JAMES ISLAND, S.C. (WCBD) — Homeowners in the Town of James Island are slated to receive lower premiums for flood insurance starting this fall.
Officials said Thursday that the town's designation in FEMA's Community Rating System — a voluntary incentive program — was bumped up to Class 5 as a result of ongoing efforts to reduce the risk of flooding.
That means policyholders within the town are set to get an additional 5% in savings on flood insurance policies, bringing the total discount to 25% starting in October.
According to FEMA data, the median cost of insurance for a single-family home through the National Flood Insurance Program was $797 in August 2023.
Joint Base Charleston seeking public input on environmental restoration program
The town has implemented a range of preventative measures in recent years to help mitigate flooding, including adopting stronger building standards to ensure buildings in low-lying areas can withstand worsening storm surges.
'By strengthening our flooding program and adopting stricter development requirements, we've been able to help our residents cut their flood insurance bills by 25%,' Mayor Brook Lyon said. 'And that's a real win for both safety and savings.'
Officials said they are hopeful recent land conservation efforts made possible by the county's Greenbelt program will help secure large discounts in the future.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
JOB ALERT: Goodwill Industries of East Texas needs a WAT Trainer
Goodwill Industries of East Texas Tyler WAT Trainer Pay: $15 – $18 an hour – Full-time The incumbent in this position is primarily responsible for working with disabled individuals to provide work adjustment training services. The individual must be able to identify appropriate/ inappropriate work behavior by observing, using existing records, DARS data, and or feedback from family members; train consumer on various job duties, workplace policies and procedures/social skills/safe and efficient operation of equipment. Education/Experience: High School Diploma or GED and a Bachelor's degree in a related field, e.g., Education, Sociology, Social Services, or Liberal Arts and one year of full-time experience performing rehabilitation or adjustment; or an AA degree in a related field and 2 years of training/experience; possess computer skills (Microsoft Office Suite, Excel/Outlook). Goodwill Industries of East Texas in Tyler is looking for a WAT Trainer. Apply Here Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. About Phathom Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at and follow on LinkedIn and StatementsThis press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Phathom's commercialization plans. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom's business, including, without limitation: the timing of the correction to the Orange Book; the expected duration of patent term extension for VOQUEZNA; we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom's ability to obtain and maintain intellectual property protection, including patent term extensions, and non-patent regulatory exclusivity for vonoprazan; Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets; Phathom's ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. MEDIA CONTACTNick Benedetto1-877-742-8466media@ INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@ © 2025 Phathom Pharmaceuticals. All rights VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
Yahoo
an hour ago
- Yahoo
ACM Research, Inc. (ACMR) is Attracting Investor Attention: Here is What You Should Know
ACM Research, Inc. (ACMR) has recently been on list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned +5.3%, compared to the Zacks S&P 500 composite's +5.3% change. During this period, the Zacks Semiconductor Equipment - Material Services industry, which ACM Research falls in, has gained 15.3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, ACM Research is expected to post earnings of $0.42 per share, indicating a change of -23.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -13.3% over the last 30 days. The consensus earnings estimate of $2 for the current fiscal year indicates a year-over-year change of -11.5%. This estimate has changed -2.2% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $2.20 indicates a change of +10% from what ACM Research is expected to report a year ago. Over the past month, the estimate has changed -12%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, ACM Research is rated Zacks Rank #4 (Sell). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of ACM Research, the consensus sales estimate of $221.04 million for the current quarter points to a year-over-year change of +9.2%. The $912.29 million and $1.06 billion estimates for the current and next fiscal years indicate changes of +16.6% and +16.6%, respectively. ACM Research reported revenues of $172.35 million in the last reported quarter, representing a year-over-year change of +13.3%. EPS of $0.46 for the same period compares with $0.52 a year ago. Compared to the Zacks Consensus Estimate of $162.5 million, the reported revenues represent a surprise of +6.06%. The EPS surprise was +24.32%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. ACM Research is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about ACM Research. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACM Research, Inc. (ACMR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
